Dataset Information


Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature.

ABSTRACT: The outcome of pancreatic cancer is poor, with a 9% 5-year survival rate. Current treatment recommendations in the 10%-20% of patients who present with resectable disease support upfront resection followed by adjuvant therapy. Until now, only early complete surgical (R0) resection and adjuvant chemotherapy (AC) with either FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) or nab-paclitaxel plus gemcitabine have been shown to prolong the survival. However, up to 30% of patients do not receive adjuvant therapy because of the development of early recurrence, postoperative complications, comorbidities, and reduced performance status. The aims of neoadjuvant chemotherapy (NAC) are to identify rapidly progressing patients to avoid futile surgery, eliminate micrometastases, increase the feasibility of R0 resection, and ensure the completion of multimodal treatment. Neoadjuvant treatments are effective, but there is no consensus on their use in resectable pancreatic cancer (RPC) because of its lack of a survival benefit over adjuvant therapy. In this review, we analyze the advantages and disadvantages of the two therapeutic approaches in RPC. We need studies that compare the two approaches and can identify the appropriate sequence of adjuvant therapy after neoadjuvant treatment and surgery.


PROVIDER: S-EPMC6912693 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7005204 | BioStudies
| S-EPMC6937851 | BioStudies
2019-01-01 | S-EPMC6416273 | BioStudies
1000-01-01 | S-EPMC6033157 | BioStudies
2019-01-01 | S-EPMC6556697 | BioStudies
2018-01-01 | S-EPMC6145728 | BioStudies
2015-01-01 | S-EPMC4699862 | BioStudies
2018-01-01 | S-EPMC6057099 | BioStudies
2015-01-01 | S-EPMC4289008 | BioStudies
2013-01-01 | S-EPMC4174603 | BioStudies